DUBLIN--(BUSINESS WIRE)--The "Vascular Adhesion Protein 1 (VAP-1) Inhibitors -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
"Vascular Adhesion Protein 1 (VAP-1) Inhibitors- Pipeline Insight, 2018" report outlays comprehensive Insight of present scenario and growth prospects across Vascular Adhesion Protein 1 (VAP-1) Inhibitors.
A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 5+ products along with 5+ companies involved.
Products covered by Phase
- Phase II
- Inactive (Dormant and Discontinued)
Overview of pipeline development activities for Vascular Adhesion Protein 1 (VAP-1) Inhibitors
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Vascular Adhesion Protein 1 (VAP-1) Inhibitors
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.
- Acorda Life Sciences
- Astellas Pharma
- Boehringer Ingelheim
- Faron Pharmaceuticals
- Sucampo Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3wdbc7/vascular_adhesion?w=4